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The wt-1 gene encodes a zinc finger DNA-binding protein that acts as a transcriptional activator or repressor depending on
the cellular or chromosomal context. The wt-1 regulates the expression of a large number of genes that have a critical role in
kidney development. Congenital obstructive nephropathy disrupts normal renal development and causes chronic progressive
interstitial fibrosis, which contributes to renal growth arrest, ultimately leading to chronic renal failure. Wt-1 is downregulated
during congenital obstructive nephropathy, leading to apoptosis. Of great interest, nitric oxide bioavailability associated with heat
shock protein 70 (Hsp70) interaction may modulate wt-1 mRNA expression, preventing obstruction-induced cell death during
neonatal unilateral ureteral obstruction. Moreover, recent genetic researches have allowed characterization of many of the complex
interactions among the individual components cited, but the realization of new biochemical, molecular, and functional experiments
as proposed in our and other research labs allows us to establish a deeper level of commitment among proteins involved and the
potential pathogenic consequences of their imbalance.
1. Wt-1 Expression and Isoforms
Thewt-1 gene encodes a zinc fingerDNA-binding protein that
acts as a transcriptional activator or repressor depending on
the cellular or chromosomal context. Wilms tumor locus was
narrowed down to a region of less than 345 kb on human
chromosome 11p13. The wt-1 mRNA has three translation
start sites resulting in three isoforms of the protein with
different molecular weights: 62–64 kDa, 52–54 kDa, and 36–
38 kDa. Typical protein WT-1 is 52–54 kDa isoform [1]. In
addition, it has 4 major isoforms, due to the insertion of
3 amino acids (KTS) between zinc fingers 3 and 4 and the
insertion of an alternatively spliced 17-amino acid segment
encoded by exon 5 in the middle of the protein [2]. Florio et
al. stated that at least 24 differentWT-1 isoforms are produced
by alternative splicing and the use of alternate translation ini-
tiation sites [3]. Previously, Scharnhorst et al. described addi-
tional WT-1 isoforms with distinct transcription-regulatory
properties, indicating further the complexity ofWT-1 expres-
sion and activity.They stated that 32WT-1 protein forms had
been described [4].
The 429-amino acid polypeptide had features suggesting
a role in transcriptional regulation: the presence of 4 zinc
finger domains and a region rich in proline and glutamine.
The conservation in structure and relative levels of the 4wt-1
mRNAspecies suggests that each encoded polypeptidemakes
a significant contribution to normal gene function. The
control of cellular proliferation and differentiation exerted
by the wt-1 gene products may involve interactions between
the 4 polypeptides with distinct targets and functions [5].
Its activity is controlled through phosphorylation by protein
kinase A (PKA). PKA-dependent WT-1 phosphorylation
(originally shown by Ye et al. [6]) results in translocation of
WT-1 from the nucleus to the cytosol, a process that interferes
with WT-1 transcriptional activities [7].
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2. WT-1 Functions on the Kidney
Development
WT-1 is required for normal formation of the genitouri-
nary system and mesothelial tissues. Wilms tumor gene
was expressed specifically in the condensed mesenchyme,
renal vesicle, and glomerular epithelium of the developing
kidney; in the related mesonephric glomeruli; and in cells
approximating these structures in tumors [8]. One of the
more significant results in the field of renal development was
the finding that knocking out the wt-1 gene in mice results
in anephric animals [9]. The other main sites of expression
were the genital ridge, fetal gonad, and mesothelium [8].
This nuclear protein may be important in the maintenance
of ovarian follicles at early stages of development [10].
Wt-1 is likely to be amaster control gene that regulates the
expression of a large number of genes that have a critical role
in kidney development [11]. Due to its roles in development
and cell proliferation, polymorphisms within the wt-1 gene
can result inmalignancies such as leukemia andWilms tumor
[7]. Wilms’ tumor 1 gene, wt-1, is homozygously mutated in
a subset of Wilms’ tumors. Heterozygous mutations in wt-1
give rise to congenital anomalies [4]. Both constitutional and
somatic mutations disrupting the DNA-binding domain of
WT-1 result in a potentially dominant-negative phenotype. In
generating inducible cell lines expressing wild-type isoforms
of WT-1 as well as WT-1 mutants, Englert et al. observed
dramatic differences in the subnuclear localization of the
induced proteins. The WT-1 isoform that binds with high
affinity to a defined DNA target, WT-1(−KTS), was diffusely
localized throughout the nucleus. In contrast, expression of
an alternative splicing variant with reduced DNA-binding
affinity,WT-1(+KTS), orWT-1 mutants with a disrupted zinc
finger domain resulted in a speckled pattern of expression
within the nucleus [12].
Localization to subnuclear clusters required the N termi-
nus of WT-1 and coexpression of a truncated WT-1 mutant
andwild-typeWT-1(−KTS) resulted in a physical association,
the redistribution ofWT-1(−KTS) fromadiffuse to a speckled
pattern, and the inhibition of its transactivational activity.
These observations suggested to the authors that different
WT-1 isoforms and WT-1 mutants have distinct subnuclear
compartments [12]. Dominant-negativeWT-1 proteins phys-
ically associate with wild-typeWT-1 in vivo andmay result in
its sequestration within subnuclear structures [12].
3. Nitric Oxide Linked to WT-1 during
Obstructive Nephropathy
Changes in wt-1 expression pattern during ontogenesis sug-
gest a significant role both during embryonic as well as during
fetal and postnatal, urogenital development. Moreover, gene
targeting studies have shown thatWt-1 is absolutely necessary
for urogenital formation at different developmental stages
[9]. Wilms tumor gene, identified as missing or mutated in
embryonic kidney cancer cells [13], is a versatile gene that
controls transitions between the mesenchymal and epithelial
state of cells in a tissue-context dependent manner [14].
It is downregulated during congenital obstructive neph-
ropathy, leading to apoptosis [15]. Congenital obstruction
is the primary cause of end-stage renal disease in children.
The kidney shows profound morphologic and functional
changes. The physiologic developmental kidney program is
disturbed in the most advanced cases, arguing for altered
temporal/spatial expression of genes which control normal
nephrogenesis [16]. However, the mechanisms underlying
chronic obstructive nephropathy have not yet been com-
pletely elucidated. Relating changes in gene expression
to phenotypic patterns in human congenital obstructive
nephropathy represent an advance in the identification of
the genes/proteins that play important roles [17].
Changes in gene expression patterns during development
and maturation of the kidney modulate a series of events that
are responsible for extraordinary structural and functional
complexity. Congenital obstructive nephropathy disrupts
normal renal development and causes chronic progressive
interstitial fibrosis, which contributes to renal growth arrest,
ultimately leading to chronic renal failure. Therefore, renal
growth and development are severely affected by obstructive
injury through complex interactions among regulators of cell
proliferation and apoptosis [15].
Major regulators of mesenchymal-epithelial transforma-
tion and collecting duct and tubular development such as
WT-1 and Sall1 are decreased with obstruction. Excessive
apoptosis is an undisputed mechanism in these processes,
mediated by decreased expression of apoptosis inhibiting
genes (bcl2, hgf, igf, bmp7) and overexpression of proapop-
totic genes like Bax and TGF-beta. Renin and angiotensin
type II receptor (AT
2
r) implicated in renal vascular develop-
ment are decreased [16].
The stimuli responsible for the induction of apoptosis are
varied and include mechanical stress secondary to pulsatile
retrograde pressure transfer from ureteric peristalsis [18],
hypoxia [19] occurring secondary to reductions in renal
blood flow in the obstructed kidney, and inflammatory
reactions [20] caused by the influx of innate immune cells
in response to chemotactic signals from the damaged renal
parenchyma. Associated oxidative stress is a phenomenon
common to all the injurious stimuli described above and
has been widely recognized by ourselves and others as a key
contributor to renal injury following obstruction [21–23].
Experimentally induced unilateral ureteral obstruction
(UUO) represents an interesting model for studying early
fibrogenesis. This model mimics the different stages of
human neonatal obstructive nephropathy leading to apopto-
sis, tubule-interstitial fibrosis, epithelial-mesenchymal tran-
sition, and tubular atrophy [20]. Further, it reflects important
aspects of inflammation that are prominent in human kidney
diseases contributing to the UUO pathophysiology [21, 24,
25], as well in chronic kidney disease (CKD) [26], revealing
useful biomarkers of renal disease progression as well as new
therapies, which are required to allow intervention before the
establishment of irreversible renal injury [27].
Studies in neonatal rats may provide insight into the
functional development of the kidney, since nephrogenesis
continues at a rapid pace up to day 8 after birth and is
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virtually complete by days 14–19. In this regard, experimen-
tally induced UUO has emerged as an interesting model for
studying neonatal hydronephrosis and for the assessment of
potential therapeutic approaches. This model mimics, in an
accelerated manner, the different stages of human neonatal
hydronephrosis leading to tubulointerstitial fibrosis, apopto-
sis, epithelial-mesenchymal transition, and tubular atrophy.
Thus, UUO in neonatal rats impairs nephrogenesis, glomeru-
lar maturation, and tubular cellular proliferation [28].
While pharmacological protection from tubular apopto-
sis is clearly likely to be of benefit to the preservation of renal
structure and function in the adult kidney, the situation in
neonatal obstruction in rodents and in utero obstruction in
humans is somewhat more nuanced. This is based on the
fact that in these cases the kidney is still passing through the
nephrogenic program, and in order for a pharmacological
agent to be of true worth, it must not only be cytoprotective
but also allow for preservation of nephrogenesis, in order that
the developing kidney achieves its optimal quota of excretory
units and hence its optimal function [23]. The younger the
age at which UUO is performed, the more severe the growth
impairment of the ipsilateral kidney [29]. Hence UUO results
in altered cell proliferation and apoptosis in the neonatal rat
kidney [15]. These processes also occur in the developing
obstructed human kidney.They aremediated by complex sig-
naling pathways, including the heat shock protein response
associated with nitric oxide (NO) interaction [30, 31].
Johannesen et al. have shown functional interactions
between the gene promoter of the main source of the
inducible nitric oxide synthase (iNOS) and WT-1, where
iNOS promoter is strain-dependently regulated [32], which
may relate to strain-dependent differences in WT-1 tran-
scription factor expression and a modulatory role of NO
in the proliferation of T cells expressing WT-1 has been
suggested [7]. Interestingly, a cytoprotective role of NO
associated with heat shock protein 70 (Hsp70) expression in
neonatal hydronephrosis was recently shown [31, 33]. A 3-
hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitor,
rosuvastatin, has a protective effect against podocyte apopto-
sis “in vitro” [34]. Renoprotection by statins has been recently
associated with increased NO availability [31, 35, 36]. After
neonatal UUO, rosuvastatin prevents apoptosis through an
increase in NO bioavailability, which in turn is linked to
higher hsp70 expression [15, 36].
Moreover, rosuvastatin (hydrophilic statin) may have
potential utility as a therapeutic option in renal diseases
that are characterized by inflammation and fibrosis, inde-
pendently of changes in blood pressure and plasma lipid
levels [37]. Randomized studies with HMG-CoA reductase
inhibitors (statins) have shown that their major adverse
effects are associated with muscle and liver toxicity. However,
rosuvastatin seems safe in this regard [38]. In addition, we
found no significant changes in either body mass or kidney
mass in rosuvastatin-treated animals [15].
Many signals may positively or negatively affect the rat
kidney after UUO by altering regulatory proteins that initiate
apoptosis and inducing changes in mitochondrial function
[20, 39]. NO is able to either induce or inhibit apoptosis in
different circumstances [40], while factors such as bcl2 have
an antiapoptotic effect [15].
Decreased NO and iNOS/hsp70 expressions associated
with wt-1 low expression were shown in obstructed kidneys
[41]. Apoptosis was induced and it was associated with an
increased bax/bcl2 ratio.
Conversely, iNOS/hsp70 upregulation and an increased
wt-1mRNA expression, without an apoptotic response, were
observed in the cortex of obstructed kidneys of rosuvastatin-
treated rats. NO also modulated hsp70 and wt-1 mRNA
expression inMadin-Darby canine kidney (MDCK) cells. “In
vivo” experiments with NOmodulators result in wt-1mRNA
expression associated with NO level [15]. Rosuvastatin may
modulatewt-1mRNA expression through renal NO bioavail-
ability, preventing neonatal obstruction-induced apoptosis
associated with Hsp70 interaction [41].
Glomerular development fundamentally relies on the
correct maturation of three cell lineages: the epithelial
(parietal and visceral epithelia of Bowman’s capsule), the
endothelial (glomerular capillaries), and the mesenchymal
(mesangial cells). The epithelial component forms the proxi-
mal end of the excretory arm of the renal tubule via reciprocal
inductive events occurring between the ureteric bud and the
metanephric mesenchyme. In order to epithelialize, the mes-
enchyme must receive and respond to bone morphogenetic
protein 7 (BMP 7) signaling and also express key isoforms of
Wilms’ tumor-1 (WT-1) zinc-finger transcription factor. We
have shown that rosuvastatin preserves both BMP-7 andWT-
1 levels in neonatal UUO [23].
Obstructive nephropathy is also associated with down-
expression of genes related to renal vascular development as
renin and angiotensin II AT
2
receptor [16]. Our group has
shown that selective blockade of angiotensin II AT
1
receptor
decreases renal interstitial fibrosis in UUO, and this effect is
associated with iNOS activity and expression [22] as well as
with hsp70 expression [42]. In addition, Hsp70 is involved
in cellular signaling pathways related to apoptosis, protein
folding, and membrane translocation and in modulating the
activity of tumor suppressor proteins, including p53 andWT-
1 [43].
It has been hypothesized that NO may participate in
the maintenance of renal function and in the maturation of
developing kidneys [44, 45].
Apoptosis is the principal mechanism that leads to tubu-
lar atrophy during the neonatal obstructive nephropathy pro-
cess. Excessive cell death is mediated by decreased expression
of apoptosis inhibiting genes like bcl2 and overexpression
of proapoptotic genes like bax. Correspondingly, 14 days
of obstruction led to the induction of apoptosis regulated
by mitochondrial signal pathway through a proapoptotic
increased bax/bcl2 ratio and, consequently, an increased
activity of caspase 3 [33].
Therefore, it may be suggested that in certain cellular
contexts, WT-1 exhibits antiapoptotic potential through the
transcriptional upregulation of bcl2 [46].
Future experiments may explore wt-1 mRNA expression
during UUO after release and its possible involvement in
renal functional and structural recovery. Recently, Yoo et al.
reported that, in complete UUO in mice, iNOS attenuates
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apoptosis and increases renal parenchymal thickness [47].
Other results corroborate previous reports in which NO has
been proposed as a key factor modulating apoptosis in UUO
[20, 33, 48, 49].
Many studies have shown the benefits of NO donors
and deleterious effects of NO inhibitors in obstructive
nephropathy. NO stimulates the expression of enzymes and
transcription factors involved in DNA repair andmodulation
of apoptosis, such as the tumor suppressor p53. In turn, p53
interacts with WT-1 and modulates its ability to regulate the
transcription of its respective target genes [50]. Consequently,
it might be expected that increased NO availability induces
p53 and wt-1 mRNA expression, as indeed shown by our
results [15]. Moreover, WT-1 can stabilize p53, adjust its
transactivational properties, and inhibit its ability to induce
apoptosis without affecting cellular arrest [51].This effectmay
explain the elevated p53 levels observed by other authors
during obstructive nephropathy apoptosis induction [52–55].
NO can oxidize intracellular glutathione and modify
cellular antioxidant levels. This stimulates heat shock protein
induction as inHsp32 andHsp70. NO generated from several
compounds induces Hsp70 expression in arterial smooth
muscle cells [56]. Hsp70 plays an important role in nascent
protein folding, reassembling denatured proteins and solubi-
lized protein aggregates [57]. Moreover, it is involved in cel-
lular signaling pathways linked to apoptosis and membrane
translocation and in themodulation of the activities of tumor
suppressor proteins, including p53 and WT-1 [58]. Inducible
Hsp70 expression has been shown to enhance the survival
of mammalian cells exposed to numerous types of stimuli
that induce stress and apoptosis [59]. Furthermore, inducible
Hsp70 protects renal epithelial cells from apoptosis by cas-
pase activation [60]. WT-1 and Hsp70 are physically associ-
ated in embryonic rat kidney cells, where the amino-terminal
transactivation domain of WT-1 is required for binding to
Hsp70, and domain expression itself is sufficient to induce
Hsp70 expression [43]. There was a significant decrease in
Hsp70 expression associated with low NO availability in
neonatal obstructed cortex [15]. Interestingly, rosuvastatin
treatment induced a significant increase in iNOS expression
and nitrite levels, and this was related to enhance Hsp70
expression. Induction of Hsp70 not only protects cells from
damage due to apoptosis induction but also from damage due
to oxidative injury. Hence, NO can induce cytoprotection in
early obstructed kidney cortex tubular epithelial cells through
the stimulation of Hsp70 expression [33]. Previously, Hegarty
et al. showed in a well characterized renal epithelial cell line
(MDCK) under mechanical strain (hydronephrosis cellular
model) an increased susceptibility to apoptosis [61]. The
cellular effects of mechanical strain were reversed by sodium
nitroprusside and L-arginine. Since about 80% of total kidney
mass is composed of tubular epithelial cells, it seems reason-
able to infer that “in vivo” results represent mostly phenom-
ena affecting this cell population. To corroborate this, basal
wt-1mRNA expression and the effects of NO availability were
also studied “in vitro” in MDCK cells. Low NO availability
was associated with low expression of Hsp70 and WT-1.
NO donors did not significantly change the Hsp70
expression, nor did the NO precursor L-arginine induce any
changes in wt-1 mRNA expression. However, wt-1 mRNA
expression was increased when MDCK cells were incubated
for 72 hours with NO donors. These results in MDCK cells
suggest a greater susceptibility to low NO levels associated
with low wt-1mRNA expression [15].
While it cannot be simply assumed that “in vitro” results
faithfully reproduce “in vivo” mechanisms, in both cases
nitric oxide levels associated with hsp70 mRNA expression
seem to modulate wt-1 mRNA expression. This proposed
mechanism is further supported by the results of treating
neonatal rats with NOmodulators, where a close relationship
between endogenous nitrite levels and wt-1/hsp70 mRNA
expression was found. The p53 protein interacts with mem-
bers of the Hsp70 chaperone family which can regulate its
function [62, 63]. In this regard, neonatal UUO shows low
p53 and Hsp70 expressions, which are increased in associ-
ation with higher NO levels under rosuvastatin treatment.
Conversely, MDCK cells with NO deprivation expressed low
hsp70 and p53 mRNA levels. These observations suggest a
potential role for NO bioavailability and Hsp70 interaction
during kidney differentiation.
In conclusion, unilateral ureteral obstruction in neonatal
rodents can be used as a paradigm for “in uteri” obstruction
in humans and a platform for studying the potential of novel
therapies for congenital obstructive nephropathy. Nitric
oxide bioavailability associated with Hsp70 interaction may
modulate wt-1 mRNA expression, preventing obstruction-
induced cell death during neonatal unilateral ureteral
obstruction.
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